RESUMEN
Cytomorphological signs of bacterial infection agents were studied by atomic force microscopy. Analysis of the elastic mechanical characteristics of Staphylococcus spp. from the skin of patients with chronic dermatoses showed lower elasticity of S. aureus cell membrane in comparison with that of transitory flora representatives. Significant differences in characteristics of cell membrane relief and presence of fimA pathogenicity factor were detected in E. coli isolated from the reproductive tract mucosa of clinically healthy women and patients with inflammatory urogenital infections.
Asunto(s)
Cuello del Útero/microbiología , Escherichia coli/aislamiento & purificación , Membrana Mucosa/microbiología , Enfermedades de la Piel/microbiología , Piel/microbiología , Staphylococcus/aislamiento & purificación , Membrana Celular/fisiología , Escherichia coli/metabolismo , Femenino , Proteínas Fimbrias/metabolismo , Humanos , Microscopía de Fuerza Atómica , Staphylococcus/clasificaciónRESUMEN
Febrile neutropenia (FN) remains a potentially life-threatening complication of anticancer chemotherapy. Bacterial translocation via intestinal mucosa is a significant mechanism of FN development. Competitive inhibition of bowel colonization by pathogenic microorganisms by lactic acid bacteria could be a useful prevention of FN. The aim of the study was the prevention of FN by probiotic strain Enterococcus faecium M-74 enriched with selenium in leukemic patients. Fourteen (six males/eight females) patients with myelogenous leukemia treated by induction or consolidation chemotherapy were included in the study. Patients received prophylaxis with E. faecium M-74 during one cycle of chemotherapy. The daily dose was 36 x 10(9) CFU tid. Prophylaxis started between day -2 and day +2 of chemotherapy and continued until the absolute neutrophile count (ANC) was >1,000/microl. All patients experienced febrile neutropenia. During 231 days of severe neutropenia, 30 febrile episodes occurred. No any febrile episode or infection provoked by the strain tested was noticed. Tolerance of therapy was excellent without significant adverse effects. Our results demonstrate the safety of the probiotic strain E. faecium M-74 enriched with selenium in leukemic patients with severe neutropenia. However, its administration was not effective in the prevention of febrile neutropenia, but this does not preclude the protective effect of other probiotic strains.
Asunto(s)
Antineoplásicos/efectos adversos , Enterococcus faecium , Fiebre/complicaciones , Neutropenia/prevención & control , Probióticos/uso terapéutico , Adulto , Anciano , Femenino , Fiebre/prevención & control , Humanos , Masculino , Persona de Mediana Edad , Neutropenia/inducido químicamente , Neutropenia/complicaciones , Neutropenia/epidemiología , Eslovaquia/epidemiologíaRESUMEN
Febrile neutropenia (FN) remains a potentially life-threatening complication of anticancer chemotherapy. Bacterial translocation via intestinal mucosa is a significant mechanism of FN development. Competitive inhibition of bowel colonization by pathogenic microorganisms by lactic acid bacteria could be a useful prevention of FN. The aim of the study was the evaluation of dose and safety of probiotic strain Enterococcus faecium M-74 enriched with organic selenium in patients with solid and hematological malignancies. Eleven (9 M/2F) patients were included in the study. In the first phase six patients with germ cell tumors treated by chemotherapy were included. They received prophylaxis by nonpathogenic strain E. faecium M-74 during 2 cycles of chemotherapy. The planned daily dose was 6 x 10(9) bacteria. Regarding the insufficient colonization of the gut, the dose was further increased up to 18 x 10(9) tid. After safety evaluation, five patients were included with relapse of acute leukemia. In patients with germ cell cancer, severe neutropenia G3/4 was noted in 10 of 12 cycles of chemotherapy. The febrile episode was not observed in any of the patients. The gut colonization by enterococci reaches 10(6) CFU/g stool. In 5 patients with acute leukemia during 127 days of severe neutropenia 12 febrile episodes occurred. There was not noted any febrile episode or infection provoked by the tested strain. Tolerance of therapy was excellent without significant undesirable effects. Optimal dose was assessed and safety of probiotic strain was evaluated in neutropenic patients with solid, or hematological malignancies. Based on these results we plan phase II study to evaluate the effectiveness of this strain in FN prophylaxis.